Peptide stability: from lyophilized powder to reconstituted vial

Key points

• Lyophilization is used to improve stability, but even in the solid state residual moisture, temperature and the excipient influence degradation [10][16].
• The main chemical pathways are deamidation of Asn/Gln, oxidation of residues such as Met, Cys and Trp, and hydrolysis of the Asp-Pro bond, which is particularly labile in acid [4][5][7][11].
• Agitation and interfaces are among the factors in aggregation. That is why the tesamorelin label says to swirl the vial and not shake it [3][9][13].
• Approved peptides set specific in-use periods after opening or reconstitution: 7 days for reconstituted tesamorelin and 56 days for the semaglutide pen [13][14].
• For an opened multi-dose vial with no manufacturer instruction, the CDC reference (based on USP 797) is to discard it at 28 days [15].

US status (October 2026): See the peptide status tracker.

A dry, cold, dark, closed vial is the most stable a peptide gets. Reconstitution starts the clock, and only the label of an approved product tells you how long that clock runs.

Peptides degrade by chemical and physical routes

If a peptide degrades in the refrigerator, the dose the patient receives is no longer the dose on the label. The chemistry is well described. The reference reviews separate two families of problems: chemical instability (bonds are broken or modified) and physical instability (the molecule loses its structure, aggregates or sticks to surfaces), and show that the two are interrelated [1]. Aggregation and misfolding during storage are also a concern because of possible immunogenicity [2].

The presentation changes the risk. Products are frozen or freeze-dried precisely to improve their stability [10]. Lyophilized powder is still not inert: in a lyophilized model hexapeptide, residual moisture, temperature and above all the type of bulking agent significantly influenced solid-state degradation [16]. In practice, the closed vial kept dry, cold and away from light is the most favorable condition. Reconstitution starts the clock.

• 2 to 50 years: deamidation half-times of some sequences at pH 7.4 and 37 °C [4]
• Over 89%: recovery with the right container, 1% albumin and lyophilization [8]
• 7 days: maximum use of tesamorelin after reconstitution with bacteriostatic water [13]

Deamidation, oxidation and hydrolysis are the chemical pathways

Deamidation. Asparagine (Asn) and glutamine (Gln) residues lose their amide group non-enzymatically. The rate depends strongly on neighboring amino acids. A study that measured 52 Gln and 52 Asn pentapeptides at pH 7.4 and 37 °C built a model for 648 sequence combinations, with half-times that in some cases reach 2 to 50 years [4]. Two Asn-containing peptides can behave very differently.

Oxidation. Photooxidation mainly affects tryptophan, tyrosine, phenylalanine and cysteine/cystine [5]. Methionine oxidizes with dissolved oxygen: in a study of an antibody, thawing increased dissolved oxygen and with it methionine oxidation [11].

Hydrolysis. Aspartic acid residues are a weak point. In a model hexapeptide, Asp-X bond hydrolysis predominated at very acidic pH, while isomerization predominated above pH 6 [6]. The aspartyl-prolyl (Asp-Pro) bond is particularly acid-labile, so much so that it is exploited to cleave proteins in the laboratory [7].

Aggregation, agitation and surfaces are the physical pathways

Peptide aggregation depends on intrinsic and external factors: sequence, concentration, pH, net charge, excipients, surfaces and interfaces, impurities, temperature, agitation and lyophilization [3]. In insulin, the proposed model attributes to the air-water interface the formation of the intermediates that give rise to fibril nuclei. Agitation altered the kinetics, and acidic pH shortened the lag time compared with neutral pH [9]. Hence the tesamorelin label instruction: swirl the vial in a circle, do not shake, and let it rest until the foam separates [13].

Adsorption is the silent loss. When eight endocrine peptides were incubated for 48 hours in glass and plastic tubes, surface binding varied widely by material. Siliconization reduced recovery and 1% albumin improved it. Lyophilized with albumin in the best container for each peptide, recovery exceeded 89% [8]. Nominal and actual concentration may not match, especially in dilute solutions.

Freezing is not an automatic refuge

During cooling, low temperature, freeze-concentration and ice formation stress the molecule [10]. In the antibody study, benzyl alcohol worsened aggregation induced by freeze-thaw cycles. The authors recommend avoiding freezing formulations with this preservative and keeping reconstituted products at 2 to 8 °C [11]. Approved labels point the same way: semaglutide must not be frozen, or used if it was frozen, and must be protected from light [14]. Tesamorelin vials are kept out of the light and not frozen [13].

Bacteriostatic water protects the vial between punctures

Bacteriostatic water for injection is sterile water with 0.9% (9 mg/mL) or 1.1% benzyl alcohol as a preservative, in a multiple-dose container from which repeated withdrawals may be made [12]. Sterile water without preservative does not offer that protection against contamination between punctures. The diluent label adds two warnings: it must not be used in neonates because of benzyl alcohol toxicity, and reconstituted solutions should not be stored unless the drug manufacturer directs otherwise [12].

Whether the preservative harms the peptide depends on the molecule. In the antibody studied, benzyl alcohol synergistically worsened freeze-thaw-induced aggregation, and 1.1% was preferable to 2% [11]. Tesamorelin, an approved peptide, is reconstituted with bacteriostatic water [13].

Handling checklist.

1. Keep the lyophilizate dry, cold and dark.
2. Reconstitute aseptically.
3. Swirl without shaking.
4. Label the reconstitution date.
5. Refrigerate at 2 to 8 °C without freezing, unless the label says otherwise (reconstituted tesamorelin, for example, is kept at 20 to 25 °C and not refrigerated).
6. Choose suitable containers for dilute solutions.
7. Discard if cloudy, particulate or discolored [8][11][12][13][15].

Approved labels set the in-use periods

Approved peptides provide the best reference point, because their in-use periods come from their own stability studies. After first use, the semaglutide pen can be kept for 56 days at 15 to 30 °C or refrigerated [14]. Reconstituted tesamorelin is kept at 20 to 25 °C and discarded 7 days after mixing, while the bacteriostatic water bottle is discarded 28 days after first use [13]. For multi-dose vials in general, the CDC, based on USP chapter 797, says to date them when opened and discard them within 28 days unless the manufacturer states otherwise [15]. That is the logic of the 28-day limit used in reconstitution calculators: a sterility ceiling for the multi-dose vial, with no guarantee of the peptide’s chemical stability.

Most peptides have no reconstituted stability data

Most peptides sold outside approved products have no published stability data in their reconstituted form. The principles above come mainly from therapeutic proteins, model peptides and approved drugs [1][3][6], and the literature itself recognizes that deamidation rates vary markedly with sequence [4]. Extrapolating semaglutide’s 56-day period, which depends on a specific formulation and container, to a reconstituted vial of another peptide is not supported [14].

What this means for your clinic

Treat any in-use period that does not come from a label as an assumption. Document it, and when the result matters, verify compound integrity by analytical methods. Stability is half the problem. The other half is what was in the vial to begin with: see what lab tests find in peptide vials, the supplier diligence checklist and 503A vs 503B sourcing.

References

1. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. PMID 20143256. Link
2. Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov. 2005;4(4):298-306. PMID 15803194. Link
3. Zapadka KL, Becher FJ, Gomes Dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7(6):20170030. PMID 29147559. Link
4. Robinson NE, et al. Structure-dependent nonenzymatic deamidation of glutaminyl and asparaginyl pentapeptides. J Pept Res. 2004;63(5):426-436. PMID 15140160. Link
5. Kerwin BA, Remmele RL Jr. Protect from light: photodegradation and protein biologics. J Pharm Sci. 2007;96(6):1468-1479. PMID 17230445. Link
6. Oliyai C, Borchardt RT. Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide. Pharm Res. 1993;10(1):95-102. PMID 8430066. Link
7. Fung EN, et al. Targeting an acid labile aspartyl-prolyl amide bond as a viable alternative to trypsin digestion to generate a surrogate peptide for LC-MS/MS analysis. Bioanalysis. 2014;6(22):2985-2998. PMID 25496253. Link
8. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. PMID 21315060. Link
9. Nielsen L, et al. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry. 2001;40(20):6036-6046. PMID 11352739. Link
10. Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2007;12(5):505-523. PMID 17963151. Link
11. Xu ZT, Yang CH, Liu W, Qian C, Fang WJ. Benzyl alcohol exacerbates freeze-thaw-induced aggregation of trastuzumab: elucidating mechanisms and formulation implications for clinical practice. Int J Pharm. 2026;688:126433. PMID 41325828. Link
12. Hospira, Inc. Bacteriostatic Water for Injection, USP. Prescribing information (DailyMed, updated 22 May 2026). Link
13. Theratechnologies Inc. EGRIFTA WR (tesamorelin) for injection. Prescribing information, revised 03/2025 (DailyMed). Link
14. Novo Nordisk. OZEMPIC (semaglutide) injection. Prescribing information (DailyMed, updated 1 June 2026). Link
15. Centers for Disease Control and Prevention. Injection safety: clinical safety, key points for multi-dose vials. Link
16. Oliyai C, Patel JP, Carr L, Borchardt RT. Chemical pathways of peptide degradation. VII. Solid state chemical instability of an aspartyl residue in a model hexapeptide. Pharm Res. 1994;11(6):901-908. PMID 7937533. Link

This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.